Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Police have charged a Reserve Township woman with delivering the bone-breaking punch that caused her 73-year-old mother’s ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Upstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

TUESDAY, July 1, 2025 (HealthDay News) — Digital inhalers may help predict the occurrence of acute exacerbations of chronic ...

The deal gives Merck control of Verona’s Ohtuvayre, a newly approved treatment for chronic obstructive pulmonary disease ...